Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.jvca.2009.01.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phenotypic Expression and Outcomes in Patients with the p.Arg301Gln Variant in Anderson-Fabry Disease.
Int J Mol Sci
April 2024
Cardiology Department, Hospital Universitario Son Llatzer, 07198 Palma de Mallorca, Spain.
Article Synopsis
- * It analyzed data from 49 patients, revealing a 63% penetrance and showing that men had earlier symptom onset compared to women, with only 20% presenting the classic AFD symptoms.
- * Nearly 20% of patients experienced significant cardiovascular and renal events, and the study highlights the importance of understanding this variant's effects for better clinical management and awareness of AFD progression.
Clinical use of tissue plasminogen activator for systemic thrombolysis in dogs and cats.
J Vet Cardiol
June 2022
Department of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, 1678 Campus Delivery, Fort Collins, CO, 80523-1678, USA. Electronic address:
Introduction: Systemic administration of tissue plasminogen activator (tPA) is seldomly reported in dogs and cats.
Animals: Client-owned animals receiving tPA (2010-2020).
Materials And Methods: Medical records of dogs and cats receiving tPA for distant known/suspected thrombus were reviewed.
Adverse Events Following Transcatheter Edge-to-Edge Repair (TEER) Using MitraClip: Lessons Learned From the Manufacturer and User Facility Device Experience (MAUDE) Registry.
Cardiovasc Revasc Med
June 2022
Division of Cardiology, Department of Medicine, Vanderbilt University School of Medicine, United States of America.
Objective: The MitraClip from Abbott is FDA approved intracardiac implantable device for transcatheter edge-to-edge repair (TEER). Despite a few previously published studies, there is limited safety data for its use in clinical practice, hence, we designed this study using data obtained from a safety nationwide database to demonstrate the safety profile of MitraClip.
Methods: The first two of the five authors independently queried all reported adverse events from the United State Food and Drug Administration [FDA] Manufacturer and User Facility Device Experience [MAUDE] registry from January 2014 to December 2020.
Thrombolysis with Systemic Recombinant Tissue Plasminogen Activator in Children: A Multicenter Retrospective Study.
Turk J Haematol
December 2021
University of Health Sciences Turkey, Ankara City Hospital, Department of Pediatrics, Division of Pediatric Hematology, Ankara, Turkey
Objective: This study aimed to evaluate systemic thrombolysis experiences with recombinant tissue plasminogen activator (rtPA).
Materials And Methods: Retrospective data were collected from 13 Turkish pediatric hematology centers. The dose and duration of rtPA treatment, concomitant anticoagulant treatment, complete clot resolution (CCR), partial clot resolution (PCR), and bleeding complications were evaluated.
Early discharge and home treatment of patients with low-risk pulmonary embolism with the oral factor Xa inhibitor rivaroxaban: an international multicentre single-arm clinical trial.
Eur Heart J
January 2020
Center for Thrombosis and Hemostasis (CTH), University Medical Center of the Johannes Gutenberg University, Langenbeckstrasse 1, Building 403, 55131 Mainz, Germany.
Aims: To investigate the efficacy and safety of early transition from hospital to ambulatory treatment in low-risk acute PE, using the oral factor Xa inhibitor rivaroxaban.
Methods And Results: We conducted a prospective multicentre single-arm investigator initiated and academically sponsored management trial in patients with acute low-risk PE (EudraCT Identifier 2013-001657-28). Eligibility criteria included absence of (i) haemodynamic instability, (ii) right ventricular dysfunction or intracardiac thrombi, and (iii) serious comorbidities.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!